Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
Facility of bone marrow transplant at IGIMS soon
on April 18, 2018 at 1:30 pm
PATNA: The Indira Gandhi Institute of Medical Sciences (IGIMS) would conduct bone marrow transplant and stem cell therapy from the first week of June, IGIMS medical superintendent Dr Manish Mandal said on Wednesday. IGIMS will be the first government ... […]
Appeal to community for stem cell donor to save grandmother’s live
on April 18, 2018 at 10:40 am
She had one round of chemotherapy which seemed to work, but after a third round she was told that she would need a stem cell transplant.” The family — father Ronnie, Adam and his brother Daniel — have made contact with the Anthony Nolan Trust which ... […]
Autologous Stem Cell and Non-Stem Cell Based Therapies Market is Determined to Cross US$ 4.5 Billion By 2022
on April 18, 2018 at 7:07 am
Based on application, the market is segmented into Treating neurodegenerative, Autoimmune, Cardiovascular disorders skin transplant, Oncology and Other. The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is expected to exceed more ... […]
Can stem cell therapy help in treating haemophilia?
on April 18, 2018 at 5:56 am
More recently, Regenerative Medicine researchers have propagated cell-based therapy as an attractive option for transplantation of healthy cells with the required clothing factor for the treatment of haemophilia. Hematopoietic stem cells, autologous dermal ... […]
Man celebrating anniversary of stem cell transplant—But who’s next to him—stops dead in his tracks
on April 14, 2018 at 1:37 pm
When family and friends sing “Happy Birthday” in a public place it typically attracts attention. So when Bruce Becke’s family sang happy birthday to him as he sat with a large birthday cake in front of him, the table next to him couldn’t help but ... […]
ABMDR Donor’s Stem Cells Rushed to Iran for Life-Saving Transplant
on April 11, 2018 at 3:09 pm
The patient’s only hope for survival is to undergo bone marrow stem cell transplantation. The transplant will be the 31st to be facilitated by the Armenian Bone Marrow Donor Registry. Dr. Georgi Iloyan, the donor of the stem cells, is an acclaimed ... […]
Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies
on April 11, 2018 at 11:41 am
1 Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, Université d’Aix-Marseille, INSERM CBT 1409, Centre d’Investigations Cliniques en Biothérapie, F-13009 Marseille, France. 2 Laboratory of Translational Immunology and Department of ... […]
Stem Cell Treatment Offers Hope for Sickle Cell Anemia Cure
on April 10, 2018 at 3:41 pm
The disease was reversed in a Canadian woman using a bone marrow transplant involving stem cells. Researchers hope the method will work for others. Credit: Getty Images A therapy for sickle cell anemia could give new hope to people with the disease ... […]
Stem Cell Discovery Could Improve Bone Marrow Transplantation
on April 10, 2018 at 10:06 am
New findings about hematopoietic stem cells—which give rise to all blood cells—could lead to improvements in bone marrow transplantation, say scientists at Columbia University Vagelos College of Physicians and Surgeons and the Columbia Stem Cell ... […]
Despite FDA crackdown, stem cell therapy still ‘wild west’
on April 6, 2018 at 2:03 am
Last year he traveled to India and paid $30,000 for a procedure known as hematopoietic stem cell transplant, which uses chemotherapy and blood-forming stem cells. The procedure involved using chemo drugs to destroy his immune system, drawing blood from his ... […]
via Google News and Bing News